Christoph Rösli appointed Head of Platforms

On 1 April, Christoph Rösli joined Swiss TPH as Head of Platforms. In this role, he will lead Swiss TPH’s scientific platforms and core facilities, which include Biostatistics and Data Management, the Central Laboratory, Cohorts and Biobanks, Projects and Grants and Research Informatics.

“I am very pleased to welcome Christoph Rösli to Swiss TPH. He brings a wealth of expertise and experience from the academic and private sector as well as in-depth knowledge directing scientific platforms across diverse settings and leading organisational changes,” said Jürg Utzinger, Director of Swiss TPH. 

Rösli has worked for over 15 years in academic institutions and the pharmaceutical industry, leading research and development projects and developing scientific platforms.

Before joining Swiss TPH, he served as the Director of Research Platforms at CSL Behring in Bern, Switzerland, where he led scientific platforms in gene therapy and analytical biochemistry and oversaw a research portfolio spanning from transplantation and immunology to cardiovascular and renal diseases. Prior to this, he held leadership roles at Novartis Pharma AG in Basel and Sandoz Biopharmaceuticals in Germany.

“I’m excited to join Swiss TPH and contribute to advancing global health, “said Rösli. “Scientific platforms and core facilities are critical enablers of innovative and impactful research. I look forward to working closely with colleagues across the institute to further develop and strengthen these platforms and facilities, and to fostering an environment of innovation and collaboration.”

Rösli holds a PhD in Pharmaceutical Sciences from ETH Zürich and completed a Postdoctoral Research Fellowship at the Institute of Pharmaceutical Sciences at ETH Zürich. He has been a member of the selection board of BaseLaunch, one of Europe’s leading biotech accelerators, and contributed to numerous research publications and two patents.